S7326

SB 657510

≥98% (HPLC)

• 別名: 2-Bromo-N-[4-chloro-3-[[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]-4,5-dimethoxy-benzenesulfonamide, SB-657510
• 実験式（ヒル表記法）: C₁₉H₂₂BrClN₂O₅S
• CAS番号: 474960-44-6
• 分子量: 505.81
• UNSPSCコード: 12352200
• PubChem Substance ID: 329824581
• NACRES: NA.77

特性

• 品質水準: 100
• アッセイ: ≥98% (HPLC)
• フォーム: powder
• 色: white to off-white
• 溶解性: DMSO: ≥30 mg/mL
• オーガナイザー: GlaxoSmithKline
• 保管温度: room temp
• SMILES記法: COc1cc(Br)c(cc1OC)S(=O)(=O)Nc2ccc(Cl)c(O[C@@H]3CCN(C)C3)c2
• InChI: 1S/C19H22BrClN2O5S/c1-23-7-6-13(11-23)28-16-8-12(4-5-15(16)21)22-29(24,25)19-10-18(27-3)17(26-2)9-14(19)20/h4-5,8-10,13,22H,6-7,11H2,1-3H3/t13-/m1/s1
• InChI Key: KQCZCINJGIRLCD-CYBMUJFWSA-N

詳細

アプリケーション

SB 657510 may be used to study the urotensin II receptor-mediated signaling.

生物化学的／生理学的作用

SB 657510 is a potent and selective urotensin-II (UT) receptor antagonist.

SB 657510 slows development of diabetes-associated atherosclerosis in mouse model of diabetes.¹

SB-657510 is a selective urotensin-II (UT) receptor antagonist. Human urotensin-II (hU-II) is proposed to play a significant role in cardiorenal and metabolic disease states, including heart failure, atherosclerosis, hypertension.

特徴および利点

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

安全性情報

• ピクトグラム: GHS07
• シグナルワード: Warning
• 危険有害性情報: H315,H319,H335
• 注意書き: P261 - P264 - P271 - P280 - P302 + P352 - P305 + P351 + P338
• 危険有害性の分類: Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
• ターゲットの組織: Respiratory system
• 保管分類コード: 11 - Combustible Solids
• WGK: WGK 3
• 引火点(°F): Not applicable
• 引火点(℃): Not applicable